Enolase subunits in patients with neuroendocrine tumors.
Concentrations of the alpha-, beta-, and gamma-subunits of enolase in surgically resected tumors and serum obtained from patients with various endocrine tumors were measured by a sensitive enzyme immunoassay system. Tissue concentrations of the gamma-subunit were significantly elevated in patients with neuroendocrine tumors concurrent with high concentrations of the gamma-subunit in their serum, which fell to normal in 90% of those who underwent tumor resection. Immunohistochemical analysis revealed that considerable amounts of the gamma-subunit were contained specifically in these tumors. These results indicate that the gamma-subunit of enolase is a useful marker for diagnosing and monitoring patients with neuroendocrine tumors.
D000328:Adult; D002116:Calcitonin / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002277:Carcinoma / Q000201:enzymology / Q000628:therapy; D004700:Endocrine System Diseases / Q000201:enzymology*; D006651:Histocytochemistry; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D009369:Neoplasms / Q000201:enzymology*; D010446:Peptide Fragments / Q000032:analysis* / Q000097:blood; D010751:Phosphopyruvate Hydratase / Q000032:analysis* / Q000097:blood; D013964:Thyroid Neoplasms / Q000201:enzymology / Q000628:therapy
D002272:Carcinoembryonic Antigen; D010446:Peptide Fragments; D002116:Calcitonin; D010751:Phosphopyruvate Hydratase